A data-driven model of biomarker changes in sporadic Alzheimer's disease
We demonstrate the use of a probabilistic generative model to explore the biomarker changes occurring as Alzheimer's disease develops and progresses. We enhanced the recently introduced event-based model for use with a multi-modal sporadic disease data set. This allows us to determine the seque...
Saved in:
| Published in | Brain (London, England : 1878) Vol. 137; no. Pt 9; pp. 2564 - 2577 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Oxford University Press
01.09.2014
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1460-2156 0006-8950 1460-2156 |
| DOI | 10.1093/brain/awu176 |
Cover
Loading…
| Abstract | We demonstrate the use of a probabilistic generative model to explore the biomarker changes occurring as Alzheimer's disease develops and progresses. We enhanced the recently introduced event-based model for use with a multi-modal sporadic disease data set. This allows us to determine the sequence in which Alzheimer's disease biomarkers become abnormal without reliance on a priori clinical diagnostic information or explicit biomarker cut points. The model also characterizes the uncertainty in the ordering and provides a natural patient staging system. Two hundred and eighty-five subjects (92 cognitively normal, 129 mild cognitive impairment, 64 Alzheimer's disease) were selected from the Alzheimer's Disease Neuroimaging Initiative with measurements of 14 Alzheimer's disease-related biomarkers including cerebrospinal fluid proteins, regional magnetic resonance imaging brain volume and rates of atrophy measures, and cognitive test scores. We used the event-based model to determine the sequence of biomarker abnormality and its uncertainty in various population subgroups. We used patient stages assigned by the event-based model to discriminate cognitively normal subjects from those with Alzheimer's disease, and predict conversion from mild cognitive impairment to Alzheimer's disease and cognitively normal to mild cognitive impairment. The model predicts that cerebrospinal fluid levels become abnormal first, followed by rates of atrophy, then cognitive test scores, and finally regional brain volumes. In amyloid-positive (cerebrospinal fluid amyloid-β1-42 < 192 pg/ml) or APOE-positive (one or more APOE4 alleles) subjects, the model predicts with high confidence that the cerebrospinal fluid biomarkers become abnormal in a distinct sequence: amyloid-β1-42, phosphorylated tau, total tau. However, in the broader population total tau and phosphorylated tau are found to be earlier cerebrospinal fluid markers than amyloid-β1-42, albeit with more uncertainty. The model's staging system strongly separates cognitively normal and Alzheimer's disease subjects (maximum classification accuracy of 99%), and predicts conversion from mild cognitive impairment to Alzheimer's disease (maximum balanced accuracy of 77% over 3 years), and from cognitively normal to mild cognitive impairment (maximum balanced accuracy of 76% over 5 years). By fitting Cox proportional hazards models, we find that baseline model stage is a significant risk factor for conversion from both mild cognitive impairment to Alzheimer's disease (P = 2.06 × 10(-7)) and cognitively normal to mild cognitive impairment (P = 0.033). The data-driven model we describe supports hypothetical models of biomarker ordering in amyloid-positive and APOE-positive subjects, but suggests that biomarker ordering in the wider population may diverge from this sequence. The model provides useful disease staging information across the full spectrum of disease progression, from cognitively normal to mild cognitive impairment to Alzheimer's disease. This approach has broad application across neurodegenerative disease, providing insights into disease biology, as well as staging and prognostication. |
|---|---|
| AbstractList | We demonstrate the use of a probabilistic generative model to explore the biomarker changes occurring as Alzheimer's disease develops and progresses. We enhanced the recently introduced event-based model for use with a multi-modal sporadic disease data set. This allows us to determine the sequence in which Alzheimer's disease biomarkers become abnormal without reliance on a priori clinical diagnostic information or explicit biomarker cut points. The model also characterizes the uncertainty in the ordering and provides a natural patient staging system. Two hundred and eighty-five subjects (92 cognitively normal, 129 mild cognitive impairment, 64 Alzheimer's disease) were selected from the Alzheimer's Disease Neuroimaging Initiative with measurements of 14 Alzheimer's disease-related biomarkers including cerebrospinal fluid proteins, regional magnetic resonance imaging brain volume and rates of atrophy measures, and cognitive test scores. We used the event-based model to determine the sequence of biomarker abnormality and its uncertainty in various population subgroups. We used patient stages assigned by the event-based model to discriminate cognitively normal subjects from those with Alzheimer's disease, and predict conversion from mild cognitive impairment to Alzheimer's disease and cognitively normal to mild cognitive impairment. The model predicts that cerebrospinal fluid levels become abnormal first, followed by rates of atrophy, then cognitive test scores, and finally regional brain volumes. In amyloid-positive (cerebrospinal fluid amyloid-β1-42 < 192 pg/ml) or APOE-positive (one or more APOE4 alleles) subjects, the model predicts with high confidence that the cerebrospinal fluid biomarkers become abnormal in a distinct sequence: amyloid-β1-42, phosphorylated tau, total tau. However, in the broader population total tau and phosphorylated tau are found to be earlier cerebrospinal fluid markers than amyloid-β1-42, albeit with more uncertainty. The model's staging system strongly separates cognitively normal and Alzheimer's disease subjects (maximum classification accuracy of 99%), and predicts conversion from mild cognitive impairment to Alzheimer's disease (maximum balanced accuracy of 77% over 3 years), and from cognitively normal to mild cognitive impairment (maximum balanced accuracy of 76% over 5 years). By fitting Cox proportional hazards models, we find that baseline model stage is a significant risk factor for conversion from both mild cognitive impairment to Alzheimer's disease (P = 2.06 × 10(-7)) and cognitively normal to mild cognitive impairment (P = 0.033). The data-driven model we describe supports hypothetical models of biomarker ordering in amyloid-positive and APOE-positive subjects, but suggests that biomarker ordering in the wider population may diverge from this sequence. The model provides useful disease staging information across the full spectrum of disease progression, from cognitively normal to mild cognitive impairment to Alzheimer's disease. This approach has broad application across neurodegenerative disease, providing insights into disease biology, as well as staging and prognostication. Young et al. reformulate an event-based model for the progression of Alzheimer's disease to make it applicable to a heterogeneous sporadic disease population. The enhanced model predicts the ordering of biomarker abnormality in sporadic Alzheimer's disease independently of clinical diagnoses or biomarker cut-points, and shows state-of-the-art diagnostic classification performance. We demonstrate the use of a probabilistic generative model to explore the biomarker changes occurring as Alzheimer’s disease develops and progresses. We enhanced the recently introduced event-based model for use with a multi-modal sporadic disease data set. This allows us to determine the sequence in which Alzheimer’s disease biomarkers become abnormal without reliance on a priori clinical diagnostic information or explicit biomarker cut points. The model also characterizes the uncertainty in the ordering and provides a natural patient staging system. Two hundred and eighty-five subjects (92 cognitively normal, 129 mild cognitive impairment, 64 Alzheimer’s disease) were selected from the Alzheimer’s Disease Neuroimaging Initiative with measurements of 14 Alzheimer’s disease-related biomarkers including cerebrospinal fluid proteins, regional magnetic resonance imaging brain volume and rates of atrophy measures, and cognitive test scores. We used the event-based model to determine the sequence of biomarker abnormality and its uncertainty in various population subgroups. We used patient stages assigned by the event-based model to discriminate cognitively normal subjects from those with Alzheimer’s disease, and predict conversion from mild cognitive impairment to Alzheimer’s disease and cognitively normal to mild cognitive impairment. The model predicts that cerebrospinal fluid levels become abnormal first, followed by rates of atrophy, then cognitive test scores, and finally regional brain volumes. In amyloid-positive (cerebrospinal fluid amyloid-β 1–42 < 192 pg/ml) or APOE-positive (one or more APOE4 alleles) subjects, the model predicts with high confidence that the cerebrospinal fluid biomarkers become abnormal in a distinct sequence: amyloid-β 1–42 , phosphorylated tau, total tau. However, in the broader population total tau and phosphorylated tau are found to be earlier cerebrospinal fluid markers than amyloid-β 1–42 , albeit with more uncertainty. The model’s staging system strongly separates cognitively normal and Alzheimer’s disease subjects (maximum classification accuracy of 99%), and predicts conversion from mild cognitive impairment to Alzheimer’s disease (maximum balanced accuracy of 77% over 3 years), and from cognitively normal to mild cognitive impairment (maximum balanced accuracy of 76% over 5 years). By fitting Cox proportional hazards models, we find that baseline model stage is a significant risk factor for conversion from both mild cognitive impairment to Alzheimer’s disease ( P = 2.06 × 10 −7 ) and cognitively normal to mild cognitive impairment ( P = 0.033). The data-driven model we describe supports hypothetical models of biomarker ordering in amyloid-positive and APOE-positive subjects, but suggests that biomarker ordering in the wider population may diverge from this sequence. The model provides useful disease staging information across the full spectrum of disease progression, from cognitively normal to mild cognitive impairment to Alzheimer’s disease. This approach has broad application across neurodegenerative disease, providing insights into disease biology, as well as staging and prognostication. We demonstrate the use of a probabilistic generative model to explore the biomarker changes occurring as Alzheimer's disease develops and progresses. We enhanced the recently introduced event-based model for use with a multi-modal sporadic disease data set. This allows us to determine the sequence in which Alzheimer's disease biomarkers become abnormal without reliance on a priori clinical diagnostic information or explicit biomarker cut points. The model also characterizes the uncertainty in the ordering and provides a natural patient staging system. Two hundred and eighty-five subjects (92 cognitively normal, 129 mild cognitive impairment, 64 Alzheimer's disease) were selected from the Alzheimer's Disease Neuroimaging Initiative with measurements of 14 Alzheimer's disease-related biomarkers including cerebrospinal fluid proteins, regional magnetic resonance imaging brain volume and rates of atrophy measures, and cognitive test scores. We used the event-based model to determine the sequence of biomarker abnormality and its uncertainty in various population subgroups. We used patient stages assigned by the event-based model to discriminate cognitively normal subjects from those with Alzheimer's disease, and predict conversion from mild cognitive impairment to Alzheimer's disease and cognitively normal to mild cognitive impairment. The model predicts that cerebrospinal fluid levels become abnormal first, followed by rates of atrophy, then cognitive test scores, and finally regional brain volumes. In amyloid-positive (cerebrospinal fluid amyloid-β1-42 < 192 pg/ml) or APOE-positive (one or more APOE4 alleles) subjects, the model predicts with high confidence that the cerebrospinal fluid biomarkers become abnormal in a distinct sequence: amyloid-β1-42, phosphorylated tau, total tau. However, in the broader population total tau and phosphorylated tau are found to be earlier cerebrospinal fluid markers than amyloid-β1-42, albeit with more uncertainty. The model's staging system strongly separates cognitively normal and Alzheimer's disease subjects (maximum classification accuracy of 99%), and predicts conversion from mild cognitive impairment to Alzheimer's disease (maximum balanced accuracy of 77% over 3 years), and from cognitively normal to mild cognitive impairment (maximum balanced accuracy of 76% over 5 years). By fitting Cox proportional hazards models, we find that baseline model stage is a significant risk factor for conversion from both mild cognitive impairment to Alzheimer's disease (P = 2.06 × 10(-7)) and cognitively normal to mild cognitive impairment (P = 0.033). The data-driven model we describe supports hypothetical models of biomarker ordering in amyloid-positive and APOE-positive subjects, but suggests that biomarker ordering in the wider population may diverge from this sequence. The model provides useful disease staging information across the full spectrum of disease progression, from cognitively normal to mild cognitive impairment to Alzheimer's disease. This approach has broad application across neurodegenerative disease, providing insights into disease biology, as well as staging and prognostication.We demonstrate the use of a probabilistic generative model to explore the biomarker changes occurring as Alzheimer's disease develops and progresses. We enhanced the recently introduced event-based model for use with a multi-modal sporadic disease data set. This allows us to determine the sequence in which Alzheimer's disease biomarkers become abnormal without reliance on a priori clinical diagnostic information or explicit biomarker cut points. The model also characterizes the uncertainty in the ordering and provides a natural patient staging system. Two hundred and eighty-five subjects (92 cognitively normal, 129 mild cognitive impairment, 64 Alzheimer's disease) were selected from the Alzheimer's Disease Neuroimaging Initiative with measurements of 14 Alzheimer's disease-related biomarkers including cerebrospinal fluid proteins, regional magnetic resonance imaging brain volume and rates of atrophy measures, and cognitive test scores. We used the event-based model to determine the sequence of biomarker abnormality and its uncertainty in various population subgroups. We used patient stages assigned by the event-based model to discriminate cognitively normal subjects from those with Alzheimer's disease, and predict conversion from mild cognitive impairment to Alzheimer's disease and cognitively normal to mild cognitive impairment. The model predicts that cerebrospinal fluid levels become abnormal first, followed by rates of atrophy, then cognitive test scores, and finally regional brain volumes. In amyloid-positive (cerebrospinal fluid amyloid-β1-42 < 192 pg/ml) or APOE-positive (one or more APOE4 alleles) subjects, the model predicts with high confidence that the cerebrospinal fluid biomarkers become abnormal in a distinct sequence: amyloid-β1-42, phosphorylated tau, total tau. However, in the broader population total tau and phosphorylated tau are found to be earlier cerebrospinal fluid markers than amyloid-β1-42, albeit with more uncertainty. The model's staging system strongly separates cognitively normal and Alzheimer's disease subjects (maximum classification accuracy of 99%), and predicts conversion from mild cognitive impairment to Alzheimer's disease (maximum balanced accuracy of 77% over 3 years), and from cognitively normal to mild cognitive impairment (maximum balanced accuracy of 76% over 5 years). By fitting Cox proportional hazards models, we find that baseline model stage is a significant risk factor for conversion from both mild cognitive impairment to Alzheimer's disease (P = 2.06 × 10(-7)) and cognitively normal to mild cognitive impairment (P = 0.033). The data-driven model we describe supports hypothetical models of biomarker ordering in amyloid-positive and APOE-positive subjects, but suggests that biomarker ordering in the wider population may diverge from this sequence. The model provides useful disease staging information across the full spectrum of disease progression, from cognitively normal to mild cognitive impairment to Alzheimer's disease. This approach has broad application across neurodegenerative disease, providing insights into disease biology, as well as staging and prognostication. |
| Author | Young, Alexandra L Oxtoby, Neil P Daga, Pankaj Cash, David M Fox, Nick C Alexander, Daniel C Schott, Jonathan M Ourselin, Sebastien |
| Author_xml | – sequence: 1 givenname: Alexandra L surname: Young fullname: Young, Alexandra L email: alexandra.young.11@ucl.ac.uk organization: 1 Centre for Medical Image Computing, Department of Computer Science, University College London, Gower Street, London, WC1E 6BT, UK alexandra.young.11@ucl.ac.uk – sequence: 2 givenname: Neil P surname: Oxtoby fullname: Oxtoby, Neil P organization: 1 Centre for Medical Image Computing, Department of Computer Science, University College London, Gower Street, London, WC1E 6BT, UK – sequence: 3 givenname: Pankaj surname: Daga fullname: Daga, Pankaj organization: 1 Centre for Medical Image Computing, Department of Computer Science, University College London, Gower Street, London, WC1E 6BT, UK – sequence: 4 givenname: David M surname: Cash fullname: Cash, David M email: alexandra.young.11@ucl.ac.uk organization: 1 Centre for Medical Image Computing, Department of Computer Science, University College London, Gower Street, London, WC1E 6BT, UK2 Dementia Research Centre, UCL Institute of Neurology, University College London, 8-11 Queen Square, London, WC1N 3AR, UK alexandra.young.11@ucl.ac.uk – sequence: 5 givenname: Nick C surname: Fox fullname: Fox, Nick C organization: 2 Dementia Research Centre, UCL Institute of Neurology, University College London, 8-11 Queen Square, London, WC1N 3AR, UK – sequence: 6 givenname: Sebastien surname: Ourselin fullname: Ourselin, Sebastien organization: 1 Centre for Medical Image Computing, Department of Computer Science, University College London, Gower Street, London, WC1E 6BT, UK2 Dementia Research Centre, UCL Institute of Neurology, University College London, 8-11 Queen Square, London, WC1N 3AR, UK – sequence: 7 givenname: Jonathan M surname: Schott fullname: Schott, Jonathan M organization: 2 Dementia Research Centre, UCL Institute of Neurology, University College London, 8-11 Queen Square, London, WC1N 3AR, UK – sequence: 8 givenname: Daniel C surname: Alexander fullname: Alexander, Daniel C email: alexandra.young.11@ucl.ac.uk organization: 1 Centre for Medical Image Computing, Department of Computer Science, University College London, Gower Street, London, WC1E 6BT, UK alexandra.young.11@ucl.ac.uk |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25012224$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkE1PwzAMhiMEYh9w44xyg0tZkzRpckGaJmBIk7jAuXKbdAu0yUjaIfj1VGKgcbGt19b72J6gY-edQeiCpDckVWxWBrBuBh89ycURGpNMpAklXBwf1CM0ifE1TUnGqDhFI8pTQinNxmg5xxo6SHSwO-Nw67VpsK9xaX0L4c0EXG3ArU3E1uG49QG0rfC8-doY25pwFbG20UA0Z-ikhiaa832eopf7u-fFMlk9PTwu5qtkS5ToEsalVGrg51KLHFTKtOIcOJRlBYQooErJKpNDEAqqXJpM0nrQuKiorEs2Rbc_vtu-bI2ujOsCNMU22GHfz8KDLf53nN0Ua78rMjLcnsnB4HpvEPx7b2JXtDZWpmnAGd_HgnDO8jQXhA2jl4esP8jv-9g3O4h0JQ |
| ContentType | Journal Article |
| Copyright | The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. 2014 |
| Copyright_xml | – notice: The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. – notice: The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. 2014 |
| CorporateAuthor | Alzheimer’s Disease Neuroimaging Initiative |
| CorporateAuthor_xml | – name: Alzheimer’s Disease Neuroimaging Initiative |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1093/brain/awu176 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2156 |
| EndPage | 2577 |
| ExternalDocumentID | PMC4132648 25012224 |
| Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: Canadian Institutes of Health Research – fundername: NIA NIH HHS grantid: U24 AG021886 – fundername: NIA NIH HHS grantid: U01 AG024904 |
| GroupedDBID | --- -E4 -~X .2P .55 .GJ .I3 .XZ .ZR 0R~ 1CY 1TH 23N 2WC 354 3O- 4.4 41~ 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6PF 70D AABZA AACZT AAGKA AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAVLN AAWDT AAWTL AAYJJ ABDFA ABDPE ABEJV ABEUO ABGNP ABIME ABIVO ABIXL ABJNI ABKDP ABLJU ABMNT ABNGD ABNHQ ABNKS ABPIB ABPQP ABPTD ABQLI ABQNK ABSMQ ABVGC ABWST ABXVV ABXZS ABZBJ ABZEO ACBNA ACFRR ACGFS ACIWK ACPQN ACPRK ACUFI ACUKT ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEHUL AEJOX AEKPW AEKSI AELWJ AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFQV AFFZL AFGWE AFIYH AFOFC AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGORE AGQPQ AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AI. AIJHB AJBYB AJDVS AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX ANFBD APIBT APJGH APWMN AQDSO AQKUS ARIXL ASAOO ASPBG ATDFG ATGXG ATTQO AVNTJ AVWKF AXUDD AYOIW AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BR6 BSWAC BTRTY BVRKM BZKNY C1A C45 CAG CDBKE CGR COF CS3 CUY CVF CXTWN CZ4 DAKXR DFGAJ DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EIHJH EJD ELUNK EMOBN ENERS F5P F9B FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MBLQV MBTAY MHKGH ML0 MVM N4W N9A NGC NLBLG NOMLY NOYVH NPM NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBFPC OBOKY OCZFY ODMLO OHH OHT OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RIG RNI ROL ROX ROZ RUSNO RW1 RXO RZF RZO TCN TCURE TEORI TJX TLC TMA TR2 VH1 VVN W8F WH7 WOQ X7H X7M XJT XOL YAYTL YKOAZ YQJ YSK YXANX ZCG ZGI ZKB ZKX ZXP ~91 7X8 5PM |
| ID | FETCH-LOGICAL-p196t-35889925078d67a903d955a5abbca119a2998c4898c69ac78e482f99856c28fb3 |
| ISSN | 1460-2156 0006-8950 |
| IngestDate | Thu Aug 21 13:54:16 EDT 2025 Thu Jul 10 22:49:38 EDT 2025 Mon Jul 21 05:28:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Pt 9 |
| Keywords | biomarker ordering event-based model disease progression Alzheimer’s disease biomarkers |
| Language | English |
| License | The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-p196t-35889925078d67a903d955a5abbca119a2998c4898c69ac78e482f99856c28fb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC4132648 |
| PMID | 25012224 |
| PQID | 1553707613 |
| PQPubID | 23479 |
| PageCount | 14 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4132648 proquest_miscellaneous_1553707613 pubmed_primary_25012224 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-09-01 |
| PublicationDateYYYYMMDD | 2014-09-01 |
| PublicationDate_xml | – month: 09 year: 2014 text: 2014-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Brain (London, England : 1878) |
| PublicationTitleAlternate | Brain |
| PublicationYear | 2014 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | 14991808 - Ann Neurol. 2004 Mar;55(3):306-19 6496779 - Am J Psychiatry. 1984 Nov;141(11):1356-64 23522844 - Neurobiol Aging. 2013 Aug;34(8):1996-2002 22917145 - Biomark Med. 2012 Aug;6(4):431-9 22213792 - Arch Gen Psychiatry. 2012 Jan;69(1):98-106 18302232 - J Magn Reson Imaging. 2008 Apr;27(4):685-91 20034579 - Neuroimage. 2010 Apr 1;50(2):516-23 20538373 - Neurobiol Aging. 2010 Aug;31(8):1263-74 19557866 - Ann Neurol. 2009 Jun;65(6):650-7 6610841 - Neurology. 1984 Jul;34(7):939-44 21825215 - Arch Neurol. 2011 Dec;68(12):1526-35 21181717 - Ann Neurol. 2010 Dec;68(6):825-34 20451875 - Alzheimers Dement. 2010 May;6(3):265-73 22917141 - Biomark Med. 2012 Aug;6(4):391-400 23419830 - Mol Psychiatry. 2014 Feb;19(2):148-9 20083042 - Lancet Neurol. 2010 Jan;9(1):119-28 23390179 - Neurology. 2013 Mar 12;80(11):1048-56 15074306 - Lancet. 2004 Jan 31;363(9406):392-4 17347250 - Brain. 2007 Apr;130(Pt 4):1148-58 20230901 - Neuroimage. 2010 Jul 15;51(4):1345-59 21670386 - Arch Neurol. 2011 Oct;68(10):1257-66 20139996 - Nat Rev Neurol. 2010 Feb;6(2):67-77 19251758 - Brain. 2009 Apr;132(Pt 4):1067-77 22784036 - N Engl J Med. 2012 Aug 30;367(9):795-804 21514248 - Alzheimers Dement. 2011 May;7(3):280-92 23109153 - Ann Neurol. 2012 Oct;72(4):578-86 24179825 - Neuroimage Clin. 2013 May 19;2:735-45 1759558 - Acta Neuropathol. 1991;82(4):239-59 24360540 - Neuron. 2013 Dec 18;80(6):1347-58 20451872 - Alzheimers Dement. 2010 May;6(3):239-46 12130773 - Science. 2002 Jul 19;297(5580):353-6 16401755 - Arch Neurol. 2006 Jan;63(1):155-6 21679929 - Biol Psychiatry. 2012 May 1;71(9):792-7 11113031 - Cereb Cortex. 2001 Jan;11(1):1-16 21170538 - Acta Neuropathol. 2011 Feb;121(2):171-81 14505582 - Lancet Neurol. 2003 Oct;2(10):605-13 22951070 - Lancet Neurol. 2012 Oct;11(10):868-77 19296504 - Ann Neurol. 2009 Apr;65(4):403-13 23332364 - Lancet Neurol. 2013 Feb;12(2):207-16 22281676 - Neuroimage. 2012 Apr 15;60(3):1880-9 20472326 - Neurobiol Aging. 2010 Aug;31(8):1275-83 23477989 - Lancet Neurol. 2013 Apr;12(4):357-67 20157306 - Nat Rev Neurol. 2010 Mar;6(3):131-44 21245183 - JAMA. 2011 Jan 19;305(3):275-83 11930016 - Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4703-7 23303849 - Neurology. 2013 Feb 12;80(7):648-54 |
| References_xml | – reference: 23477989 - Lancet Neurol. 2013 Apr;12(4):357-67 – reference: 1759558 - Acta Neuropathol. 1991;82(4):239-59 – reference: 23332364 - Lancet Neurol. 2013 Feb;12(2):207-16 – reference: 21514248 - Alzheimers Dement. 2011 May;7(3):280-92 – reference: 22784036 - N Engl J Med. 2012 Aug 30;367(9):795-804 – reference: 23109153 - Ann Neurol. 2012 Oct;72(4):578-86 – reference: 23303849 - Neurology. 2013 Feb 12;80(7):648-54 – reference: 21670386 - Arch Neurol. 2011 Oct;68(10):1257-66 – reference: 19557866 - Ann Neurol. 2009 Jun;65(6):650-7 – reference: 20538373 - Neurobiol Aging. 2010 Aug;31(8):1263-74 – reference: 20083042 - Lancet Neurol. 2010 Jan;9(1):119-28 – reference: 20451872 - Alzheimers Dement. 2010 May;6(3):239-46 – reference: 23419830 - Mol Psychiatry. 2014 Feb;19(2):148-9 – reference: 17347250 - Brain. 2007 Apr;130(Pt 4):1148-58 – reference: 21181717 - Ann Neurol. 2010 Dec;68(6):825-34 – reference: 21245183 - JAMA. 2011 Jan 19;305(3):275-83 – reference: 19251758 - Brain. 2009 Apr;132(Pt 4):1067-77 – reference: 20034579 - Neuroimage. 2010 Apr 1;50(2):516-23 – reference: 24179825 - Neuroimage Clin. 2013 May 19;2:735-45 – reference: 21679929 - Biol Psychiatry. 2012 May 1;71(9):792-7 – reference: 20451875 - Alzheimers Dement. 2010 May;6(3):265-73 – reference: 23390179 - Neurology. 2013 Mar 12;80(11):1048-56 – reference: 11930016 - Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4703-7 – reference: 18302232 - J Magn Reson Imaging. 2008 Apr;27(4):685-91 – reference: 14991808 - Ann Neurol. 2004 Mar;55(3):306-19 – reference: 6610841 - Neurology. 1984 Jul;34(7):939-44 – reference: 12130773 - Science. 2002 Jul 19;297(5580):353-6 – reference: 14505582 - Lancet Neurol. 2003 Oct;2(10):605-13 – reference: 6496779 - Am J Psychiatry. 1984 Nov;141(11):1356-64 – reference: 15074306 - Lancet. 2004 Jan 31;363(9406):392-4 – reference: 24360540 - Neuron. 2013 Dec 18;80(6):1347-58 – reference: 20230901 - Neuroimage. 2010 Jul 15;51(4):1345-59 – reference: 20472326 - Neurobiol Aging. 2010 Aug;31(8):1275-83 – reference: 22951070 - Lancet Neurol. 2012 Oct;11(10):868-77 – reference: 23522844 - Neurobiol Aging. 2013 Aug;34(8):1996-2002 – reference: 20139996 - Nat Rev Neurol. 2010 Feb;6(2):67-77 – reference: 11113031 - Cereb Cortex. 2001 Jan;11(1):1-16 – reference: 19296504 - Ann Neurol. 2009 Apr;65(4):403-13 – reference: 20157306 - Nat Rev Neurol. 2010 Mar;6(3):131-44 – reference: 22917141 - Biomark Med. 2012 Aug;6(4):391-400 – reference: 21170538 - Acta Neuropathol. 2011 Feb;121(2):171-81 – reference: 22213792 - Arch Gen Psychiatry. 2012 Jan;69(1):98-106 – reference: 16401755 - Arch Neurol. 2006 Jan;63(1):155-6 – reference: 22917145 - Biomark Med. 2012 Aug;6(4):431-9 – reference: 22281676 - Neuroimage. 2012 Apr 15;60(3):1880-9 – reference: 21825215 - Arch Neurol. 2011 Dec;68(12):1526-35 |
| SSID | ssj0014326 |
| Score | 2.5486815 |
| Snippet | We demonstrate the use of a probabilistic generative model to explore the biomarker changes occurring as Alzheimer's disease develops and progresses. We... Young et al. reformulate an event-based model for the progression of Alzheimer's disease to make it applicable to a heterogeneous sporadic disease population.... |
| SourceID | pubmedcentral proquest pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 2564 |
| SubjectTerms | Aged Aged, 80 and over Alzheimer Disease - cerebrospinal fluid Alzheimer Disease - diagnosis Alzheimer Disease - psychology Amyloid beta-Peptides - cerebrospinal fluid Apolipoproteins E - cerebrospinal fluid Biomarkers - cerebrospinal fluid Cognitive Dysfunction - cerebrospinal fluid Cognitive Dysfunction - diagnosis Cognitive Dysfunction - psychology Cross-Sectional Studies Databases, Factual - trends Female Follow-Up Studies Humans Longitudinal Studies Male Models, Neurological Neuropsychological Tests Original Peptide Fragments - cerebrospinal fluid tau Proteins - cerebrospinal fluid |
| Title | A data-driven model of biomarker changes in sporadic Alzheimer's disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25012224 https://www.proquest.com/docview/1553707613 https://pubmed.ncbi.nlm.nih.gov/PMC4132648 |
| Volume | 137 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBbpFkovpe-mL1Qo9GCc9UOW5GPYdgmlKTnsQm5BthTi7dYJjkPL_qH-zY4eUewSSrsXEWwnwpov34xG80DofSIVZ6DmQlaSJCQZI6HIJA2LiIllFHNQgjp3ePqVTi7J53k2Hwx-daKWdm0xKm-O5pXcRqpwDeSqs2T_Q7L-R-ECfAb5wggShvGfZDwOdIBnKBtNWbapjTb-dEq9jrppXFqvCXnV21chqzIYX9-sVGWaprBt74DG1zkSVX201Yf1H3DGO_4DTxcuVaYRwZeRd93-BL6wLK6q62Dmb3wU1qE7E_U3cXU4CNmufKB9MB11XRIx8TFX7d9SHXs0TEOe24qzI2WZl9AoBPuD9qjZFoRxGMy7RJvZ4udOaQPxsKMKwRbLKhrjZjkXP3axbTfTQcfmu4EH2IIxGEvkoBh9uOJsega6XscC3kF3E9iPmB4hcx9LBDan6evn38tlWMDkp2bqUzuxrjztZjm2ofkzLrdj6Fw8RA_cDgWPLdweoYGqH6N7UxeD8QRNxriDOmxQh9dL7FGHHepwVeM96rBH3Yctdph7ii7PP12cTULXjyPcAE-3YZpx2J3DGzAuKRN5lMo8y0QmiqIUcZwLMG14STgMNBcl44rwZAnXMlomfFmkz9BJva7VC4QVPFZSKSlVkkhGct2mIZdZruJIqjQeonf75VkA3-lDLFGr9W670H2umHa-pUP03C7XYmMLsyz2iztErLeQ_gFdS71_p65Wpqa6k-_LW3_zFbp_-Cu8Ridts1NvwF5ti7cGK78BKrKVDg |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+data-driven+model+of+biomarker+changes+in+sporadic+Alzheimer%27s+disease&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=Young%2C+Alexandra+L.&rft.au=Oxtoby%2C+Neil+P.&rft.au=Daga%2C+Pankaj&rft.au=Cash%2C+David+M.&rft.date=2014-09-01&rft.pub=Oxford+University+Press&rft.issn=0006-8950&rft.eissn=1460-2156&rft.volume=137&rft.issue=9&rft.spage=2564&rft.epage=2577&rft_id=info:doi/10.1093%2Fbrain%2Fawu176&rft_id=info%3Apmid%2F25012224&rft.externalDocID=PMC4132648 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2156&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2156&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2156&client=summon |